[Summary] 高端仿制药及改良型创新药
西藏多瑞医药股份有限公司(股票代码301075)成立于2016年,位于西藏自治区昌都市经济技术开发区,是西藏本土上市化学制药企业,2021年登陆深圳证券交易所创业板。公司采用制剂+多肽原料药+精细化工中间体三业务并行的原料制剂一体化运营模式。多肽原料药板块由全资子公司四川多瑞运营,拥有GMP标准生产基地,布局艾博韦泰、司美格鲁肽等核心品种;同时推进特色中药藏药研发,1类中药新药益肺济生颗粒已完成二期临床入组。公司构建有机合成、多肽合成双研发团队,截至2024年末拥有38项专利,2025年研发投入占营收比例达21.02%。未来将聚焦核心赛道,做强多肽产能,持续提升市场竞争力。
What does 西藏多瑞医药股份有限公司 require? Who is 多瑞医药 hiring? 多瑞医药 recruitment: 客户服务类占比最多占16%,其次是经营管理类占16%. What education can get in at 多瑞医药? 本科占比最多占44%,其次是大专占28%. High education required at 多瑞医药? 硕士占8%. Work experience required at 多瑞医药? 不限占比最多占76%,其次是3-5年占12%. Where are the job locations at 多瑞医药? 北京占比最多占60%,其次是成都占24%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows